Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma

Completed

• Conditions: Advanced Cancer; Metastatic Cancer; Oncology; Endometrial Cancer; Recurrent Cancer
• Interventions: Drug: Chemotherapy

• Registration Number: NCT05364905
• Lead Sponsor: ARCAGY/ GINECO GROUP

Brief Summary

This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-04-29
• Study First Submitted QC: 2022-05-04
• Study First Posted: 2022-05-06
• Study Start: 2022-05-09
• Primary Completion: 2022-11-22
• Study Completion: 2022-11-22
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-05
• Last Update Posted: 2023-09-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

1. Adult women ≥ 18 years at index date.
2. Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible.
3. Index date should represent at least the first* or second line** chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019.
4. do not express refusal to her personal data processing or did not express her refusal for deceased patients.

Exclusion Criteria

1. No clinical records for tumor imaging or administration of anti-cancer therapy.
2. Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion.
3. Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased).
4. Patient did not receive chemotherapy systemic treatment.
5. Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cohort 1	Chemotherapy	Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
Cohort 2	Chemotherapy	Patients in second line treatment (after one prior systemic chemotherapy) in 2019

Primary Outcome Measures

Name	Time	Method
Clinical, biological and treatment characteristics	up to 3 years	Description of the data

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	through study completion, an average of 1 year	From the date of initiation of the treatment in the corresponding line to the date of death
Progession Free Survival real world (rwPFS)	through study completion, an average of 1 year	From the date of initiation of the treatment in the corresponding line to the date of progression or death

Trial Locations

Locations (30)

Hôpital Morvan CHRU de Brest; 🇫🇷 Brest, France

Guillaume BABIN; 🇫🇷 Bordeaux, France

CHU de Dijon; 🇫🇷 Dijon, France

ICANS - Institut de cancérologie Strasbourg Europe; 🇫🇷 Strasbourg, France

Centre Léon Bérard; 🇫🇷 Lyon, France

Centre Hospitalier Victor Dupouy; 🇫🇷 Argenteuil, France

CHRU Besançon - Hôpital Jean Minjoz; 🇫🇷 Besançon, France

Sainte-Catherine Institut du Cancer Avignon-Provence; 🇫🇷 Avignon, France

Centre d'Oncologie et de Radiothérapie 37; 🇫🇷 Chambray-lès-Tours, France

Hôpital Louis Mourier; 🇫🇷 Colombes, France

Centre Hospitalier Intercommunal de Créteil; 🇫🇷 Créteil, France

Hôpital Cochin; 🇫🇷 Paris, France

Centre Georges François Leclerc; 🇫🇷 Dijon, France

Groupe Hospitalier Mutualiste de Grenoble; 🇫🇷 Grenoble, France

Centre Oscar Lambret; 🇫🇷 Lille, France

ORACLE - Centre d'Oncologie de Gentilly; 🇫🇷 Nancy, France

ICL - Centre Alexis Vautrin; 🇫🇷 Nancy, France

Hôpital Privé du Confluent; 🇫🇷 Nantes, France

Centre Antoine Lacassagne; 🇫🇷 Nice, France

Centre ONCOGARD - Institut de cancérologie du Gard; 🇫🇷 Nîmes, France

CHR Orléans; 🇫🇷 Orléans, France

Institut Curie; 🇫🇷 Paris, France

Hôpital Européen Georges Pompidou; 🇫🇷 Paris, France

Groupe Hospitalier Diaconesses - Croix Saint-Simon; 🇫🇷 Paris, France

Centre Eugène Marquis; 🇫🇷 Rennes, France

Centre CARIO - HPCA; 🇫🇷 Plérin, France

CHU de Poitiers - Hôpital de la Milétrie; 🇫🇷 Poitiers, France

ICO - Centre René Gauducheau; 🇫🇷 Saint-Herblain, France

CHU Tours - Hôpital Bretonneau; 🇫🇷 Tours, France

Gustave Roussy; 🇫🇷 Villejuif, France